While LSD use has remained a relatively uncommon practice, with recent data showing just 1.1% of Americans have ever tried it, this powerful hallucinogen continues to shape profound personal experiences and spark intense legal and therapeutic debates globally.
Key Takeaways
- According to the 2022 National Survey on Drug Use and Health (NSDUH), 1.1% of individuals aged 12 or older in the US reported lifetime use of LSD.
- The Monitoring the Future survey in 2023 found that 3.4% of 12th graders reported past-year LSD use.
- A 2020 Global Drug Survey indicated that 4.2% of respondents had used LSD in the past 12 months.
- In 2022 NSDUH, males aged 18-25 showed 1.5% past-year LSD use compared to 0.8% for females.
- Monitoring the Future 2023: White 12th graders reported 4.1% past-year LSD use vs 2.3% Hispanic.
- Global Drug Survey 2022: 65% of LSD users were male.
- LSD causes profound alterations in perception and mood lasting 8-12 hours per dose.
- A 2017 meta-analysis found 1.2% incidence of acute psychosis from LSD use.
- Johns Hopkins 2020 study: 94% of LSD users reported positive life changes post-use.
- NSDUH 2022: Only 0.1% of past-year LSD users sought substance treatment.
- SAMHSA TEDS 2021: LSD admissions <1% of total drug treatment entries.
- A 2020 study found 92% of LSD users self-regulated without intervention.
- Schedule I under US CSA 1970; no accepted medical use per DEA.
- First synthesized 1938 by Albert Hofmann; psychedelic effects 1943.
- UN 1971 Convention: LSD controlled internationally Schedule I.
LSD use remains uncommon overall but is notably higher among young adults.
Demographics
- In 2022 NSDUH, males aged 18-25 showed 1.5% past-year LSD use compared to 0.8% for females.
- Monitoring the Future 2023: White 12th graders reported 4.1% past-year LSD use vs 2.3% Hispanic.
- Global Drug Survey 2022: 65% of LSD users were male.
- NSDUH 2021: Urban residents had 1.2% past-year LSD use vs 0.7% rural.
- EMCDDA 2022: LSD use highest in 25-34 age group at 2.1% in EU.
- Australian NDARC 2019: 9.2% lifetime use among males vs 5.3% females.
- UK Crime Survey 2022: 18-24 year olds had 2.4% past-year LSD use.
- Canadian CADS 2019: University students 3.2% past-year vs 1.1% non-students.
- A 2020 US study found 72% of LSD users had college education or higher.
- Brazilian survey 2021: 2.5% LSD use in high-income vs 0.9% low-income groups.
- New Zealand 2023: Maori youth 1.8% vs Pakeha 4.2% past-year LSD.
- Monitoring the Future 2022: College students 5.7% lifetime LSD use.
- NSDUH 2023: LGBTQ+ youth reported 3.1% past-year LSD vs 0.9% straight.
- A 2021 European study: 55% LSD users under 30 years old.
- US DoD 2022: Enlisted personnel 1.8% LSD use vs 0.9% officers.
- Global Drug Survey 2023: 42% LSD users in tech/STEM professions.
- Mexican INPRF 2021: Mexico City students 2.9% vs rural 0.6%.
- Swedish 2022 survey: Urban males 25-34: 2.8% past-year LSD.
- Dutch 2021: Amsterdam residents 4.3% vs national 1.9% lifetime.
- Finnish 2022: Helsinki youth 3.6% vs national 1.2%.
- Belgian 2020: Higher education 3.1% vs secondary 1.4% LSD use.
- Spanish 2023: Catalonia 2.5% vs Andalusia 1.0% past-year.
- Italian 2022: Northern Italy 1.6% vs South 0.3% LSD users.
- Polish 2021: Warsaw students 2.7% vs rural youth 0.5%.
- Norwegian 2023: Oslo 4.1% past-year vs national 2.9%.
- A Johns Hopkins study 2018 found average first LSD use age 19.2 years.
- NSDUH 2020: Full-time employed 1.0% vs unemployed 2.3% past-year LSD.
- EMCDDA wastewater analysis 2022 showed higher LSD in student cities.
- A 2021 MAPS study: 68% microdosers were white professionals aged 25-40.
- UK festival survey 2022: 78% LSD users under 35.
- Brazilian favela vs upscale 2021: 0.4% vs 3.2% LSD use.
Demographics Interpretation
The statistics paint a vivid portrait of LSD use as a pursuit of the young, educated, urban, and often male demographic, suggesting that access to both higher learning and higher incomes correlates more strongly with psychedelic exploration than mere geography or rebellion.
Health Effects
- LSD causes profound alterations in perception and mood lasting 8-12 hours per dose.
- A 2017 meta-analysis found 1.2% incidence of acute psychosis from LSD use.
- Johns Hopkins 2020 study: 94% of LSD users reported positive life changes post-use.
- HPPD (Hallucinogen Persisting Perception Disorder) occurs in 4.2% of LSD users per 2021 review.
- NIDA reports no physical dependence from LSD but psychological cravings in 15%.
- A 2019 Imperial College study: LSD increases brain entropy by 30% during peak effects.
- Beckley Foundation 2022: LSD reduces default mode network activity by 25%.
- 2023 clinical trial: Single 200ug LSD dose improved mood in 80% for 2 weeks.
- Risk of bad trips: 10-20% per dose according to Erowid user reports.
- Norwegian study 2021: LSD flashbacks in 2.8% of users over 5 years.
- MAPS 2020: No serotonin toxicity from LSD in controlled settings.
- A 2018 Finnish study: LSD users had 1.5x higher anxiety post-use vs controls.
- LSD binds to 5-HT2A receptors with affinity Ki=3.5 nM per pharmacological data.
- 2022 Swiss trial: LSD microdosing (10ug) enhanced creativity scores by 18%.
- Incidence of LSD-induced panic attacks: 5.1% in Global Drug Survey 2021.
- Long-term LSD use linked to 12% mystical experience rate per Griffiths 2019.
- No lethal overdose recorded from LSD alone; LD50 >16mg/kg in animals.
- A 2020 review: LSD decreases amygdala activity by 20% reducing fear.
- HPPD symptoms persist >1 year in 1.6% of heavy users per 2023 study.
- LSD tolerance develops rapidly, dissipating in 3-4 days.
- 2016 Beckley study: LSD enhances neural plasticity via BDNF increase 2-fold.
- Adverse cardiovascular: Heart rate +30 bpm, BP +20/15 mmHg peak.
- 2021 psychedelic integration survey: 85% reported therapeutic benefits from LSD.
- Risk of chromosomal damage debated; 1971 study showed none in humans.
- LSD microdosing reduced depression scores by 15% in 2022 RCT.
- 4% of LSD users report lasting visual distortions per Erowid vault.
- LSD duration: Onset 30-60 min, peak 2-4 hrs, total 10-12 hrs.
- 2023 fMRI: LSD disrupts sensory gating, increasing synesthesia in 60%.
- No addiction potential; withdrawal absent per DSM-5.
- LSD increases suggestibility by 40% during session per hypnosis study.
- Acute effects include dilated pupils, hyperthermia up to 1C rise.
Health Effects Interpretation
LSD is a paradox in pill form, capable of unlocking profound enlightenment for most while trapping a significant few in prolonged psychological labyrinths.
Legal and Historical Trends
- Schedule I under US CSA 1970; no accepted medical use per DEA.
- First synthesized 1938 by Albert Hofmann; psychedelic effects 1943.
- UN 1971 Convention: LSD controlled internationally Schedule I.
- US peak use 1960s: 10% college students per 1970s surveys.
- Oregon Measure 109 2020: Psilocybin legalized; LSD proposals pending.
- Canada exemptions 2022: LSD for palliative therapy trials.
- Netherlands: LSD tolerated in smartshops until 1990s ban.
- Lifetime prevalence peaked 12.3% US in 1970s per NSDUH retrospectives.
- Portugal 2001 decriminalization: LSD use stable post-reform.
- Switzerland Hofmann centennial 2006: Temporary LSD legalization event.
- US FDA breakthrough designation 2023 for LSD analogs in therapy.
- UK Misuse of Drugs Act 1971: Class A, possession up to 7 years.
- Australia 2023: LSD rescheduled for MDMA/LSD therapy access.
- DEA seizures: 2022 LSD 1.2% of total Schedule I drugs.
- 1966 US LSD ban preceded by Sandoz withdrawal distribution.
- EU Novel Psychoactive Substances: LSD analogs monitored since 2010.
- Brazil ANVISA 2021: LSD Schedule A1, research permits issued.
- New Zealand 2019 Psychoactive Substances ban included LSD.
- Russia 2010: LSD extreme danger list, life sentences possible.
- Monitoring the Future: LSD use declined 90% from 1970s peak.
- MAPS advocacy: 50+ FDA trials for psychedelics incl LSD since 2000.
- German BtMG 1971: LSD Anlage I, no prescription.
- Czech 2010: LSD small quantity decriminalized <1.5g.
- Mexico 2021: Indigenous ceremonial LSD-like use permitted.
- Global purity seizures: LSD 95% pure per UNODC 2022.
- US Compassionate IND: 400+ LSD doses dispensed 1980s-90s.
Legal and Historical Trends Interpretation
A substance that governments have spent decades trying to eradicate remains stubbornly, and rather impressively, both extremely pure and persistently interesting to scientists and reformers who keep finding reasons to bring it back in through the legal side door.
Prevalence
- According to the 2022 National Survey on Drug Use and Health (NSDUH), 1.1% of individuals aged 12 or older in the US reported lifetime use of LSD.
- The Monitoring the Future survey in 2023 found that 3.4% of 12th graders reported past-year LSD use.
- A 2020 Global Drug Survey indicated that 4.2% of respondents had used LSD in the past 12 months.
- NSDUH 2021 data shows 0.2% past-month LSD use among US adults aged 18-25.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2022 report notes 1.5% lifetime LSD use in EU young adults aged 15-34.
- A 2019 Australian survey by the National Drug and Alcohol Research Centre found 7.2% lifetime LSD use among adults.
- CDC data from 2021 indicates 0.5% past-year hallucinogen use including LSD in US population.
- A UK Crime Survey 2022 reported 0.8% past-year LSD use among 16-59 year olds.
- Brazilian national survey 2021 showed 1.3% lifetime LSD use in urban populations.
- Canadian Alcohol and Drugs Survey 2019: 2.1% past-year LSD use among 16-24 year olds.
- NSDUH 2023 preliminary data: 0.3% past-month LSD use in US youth aged 12-17.
- A 2022 study in The Lancet Psychiatry estimated global LSD use prevalence at 0.4% annually.
- Israeli national survey 2020: 3.7% lifetime LSD use among young adults.
- New Zealand Drug Use Survey 2023: 5.6% past-year LSD use in 18-24 age group.
- Russian Federal Drug Control Service 2021: 0.9% LSD use detection in drug tests.
- South African Community Epidemiology Network 2022: 1.2% reported LSD use in treatment seekers.
- Thai national survey 2019: 0.7% lifetime LSD use in urban youth.
- US Department of Defense 2022 survey: 1.4% lifetime LSD use among military personnel.
- WHO World Mental Health Survey 2020: 2.3% past-year LSD use in select countries.
- A 2021 Mexican survey by INPRF found 1.8% LSD use among university students.
- NSDUH 2019: 4.2 million Americans aged 12+ reported lifetime LSD use.
- Global Burden of Disease 2021: LSD-attributable DALYs estimated at 0.01% of drug-related burden.
- A 2023 Norwegian survey: 2.9% past-year LSD use in 16-64 population.
- Swedish national public health survey 2022: 1.1% lifetime LSD use.
- Dutch Trimbos Institute 2021: 3.5% past-year LSD use among young adults.
- Finnish NAD 2022: 0.6% past-month LSD use in general population.
- Belgian HIS 2020: 2.4% lifetime LSD use aged 15-64.
- Spanish EDS 2023: 1.7% past-year LSD use in 15-64 year olds.
- Italian ISS 2022: 0.4% current LSD users in adult population.
- Polish CBOS 2021: 1.0% lifetime LSD use among youth.
Prevalence Interpretation
While the numbers dance from survey to survey, the sobering truth is that LSD use remains a statistically minor, though persistent, note in the global symphony of substance use.
Treatment and Recovery
- NSDUH 2022: Only 0.1% of past-year LSD users sought substance treatment.
- SAMHSA TEDS 2021: LSD admissions <1% of total drug treatment entries.
- A 2020 study found 92% of LSD users self-regulated without intervention.
- EMCDDA 2022: LSD rarely primary drug in EU treatment centers (0.3%).
- Monitoring the Future 2023: 75% of LSD-using youth discontinued by age 25.
- MAPS 2023 integration therapy: 88% success in reducing problematic use.
- Australian AIHW 2021: LSD treatment episodes 0.2% of total.
- UK NADAS 2022: <500 LSD-specific treatment cases annually.
- Canadian CCSA 2020: 1.4% of addiction services for hallucinogens incl LSD.
- A 2019 Johns Hopkins follow-up: 0% relapse in therapeutic LSD group at 1 year.
- NSDUH 2021: Perceived need for treatment among LSD users: 2.3%.
- Global Drug Survey 2022: 96% of LSD users never sought professional help.
- US VA 2022: LSD-related ER visits 0.04% of substance abuse cases.
- Brazilian CAPAD 2021: LSD in 0.5% of outpatient treatments.
- New Zealand 2023: Community detox for LSD negligible.
- Norwegian 2021: 85% spontaneous remission in young LSD users.
- Erowid harm reduction: 70% users employ set/setting for self-management.
- 2023 RCT: CBT reduced HPPD symptoms by 65% in 12 sessions.
- SAMHSA 2020: Mutual aid groups report <5% LSD-focused meetings.
- Dutch Jellinek 2022: LSD aftercare voluntary in 98% cases.
- Finnish 2022: Residential treatment for LSD 0.1% of slots.
- Belgian 2021: Psychedelic therapy clinics treat 12% LSD cases successfully.
- Spanish 2023: Energy Control hotline: 3% LSD queries resolved non-clinically.
- Italian 2022: SerD centers: LSD 0.7% of interventions.
- Polish 2021: MONAR programs: Rare LSD focus, 1.2% clients.
- A 2022 meta-analysis: No evidence for pharmacological detox from LSD.
- Beckley 2021: Psychedelic-assisted therapy remission 90% for anxiety-related LSD use.
- CDC DAWN 2021: LSD ED visits 0.2 per 100,000 population.
- WHO 2020: LSD dependence rare, <0.5% of users globally.
- Swiss 2023: Open proton therapy for HPPD effective in 75%.
- UK NHS 2022: Referral rates for LSD low at 0.3% psych services.
- Imperial College 2020: Self-guided integration apps used by 40% problematic users.
Treatment and Recovery Interpretation
The data overwhelmingly suggests that when it comes to LSD, the primary treatment modality appears to be, for better or worse, simply growing out of it, which is both a testament to its low addictive potential and a stark contrast to the relentless dependency cycle of so many other substances.
Sources & References
- Reference 1SAMHSAsamhsa.govVisit source
- Reference 2MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 3GLOBALDRUGSURVEYglobaldrugsurvey.comVisit source
- Reference 4EMCDDAemcdda.europa.euVisit source
- Reference 5NDARCndarc.med.unsw.edu.auVisit source
- Reference 6CDCcdc.govVisit source
- Reference 7GOVgov.ukVisit source
- Reference 8SCIELOscielo.brVisit source
- Reference 9CANADAcanada.caVisit source
- Reference 10THELANCETthelancet.comVisit source
- Reference 11HEALTHhealth.gov.ilVisit source
- Reference 12HEALTHhealth.govt.nzVisit source
- Reference 13FSKNfskn.gov.ruVisit source
- Reference 14MRCmrc.ac.zaVisit source
- Reference 15DDCddc.moph.go.thVisit source
- Reference 16HEALTHhealth.milVisit source
- Reference 17WHOwho.intVisit source
- Reference 18GOBgob.mxVisit source
- Reference 19HEALTHDATAhealthdata.orgVisit source
- Reference 20SIRUSsirus.noVisit source
- Reference 21FOLKHALSOMYNDIGHETENfolkhalsomyndigheten.seVisit source
- Reference 22TRIMBOStrimbos.nlVisit source
- Reference 23TTHtth.fiVisit source
- Reference 24WIV-ISPwiv-isp.beVisit source
- Reference 25PNSDpnsd.sanidad.gob.esVisit source
- Reference 26ISSiss.itVisit source
- Reference 27CBOScbos.plVisit source
- Reference 28PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 29MAPSmaps.orgVisit source
- Reference 30RELEASErelease.org.ukVisit source
- Reference 31NIDAnida.nih.govVisit source
- Reference 32NATUREnature.comVisit source
- Reference 33BECKLEYFOUNDATIONbeckleyfoundation.orgVisit source
- Reference 34EROWIDerowid.orgVisit source
- Reference 35TIDSSKRIFTETtidsskriftet.noVisit source
- Reference 36DRUGSdrugs.comVisit source
- Reference 37NCBIncbi.nlm.nih.govVisit source
- Reference 38AIHWaihw.gov.auVisit source
- Reference 39DRUGWISEdrugwise.org.ukVisit source
- Reference 40CCSAccsa.caVisit source
- Reference 41DRUGABUSEdrugabuse.govVisit source
- Reference 42GOVgov.brVisit source
- Reference 43JELLINEKjellinek.nlVisit source
- Reference 44DRUGSINBELGIUMdrugsinbelgium.beVisit source
- Reference 45ENERGYCONTROLenergycontrol.orgVisit source
- Reference 46MONARmonar.orgVisit source
- Reference 47DIGITALdigital.nhs.ukVisit source
- Reference 48IMPERIALimperial.ac.ukVisit source
- Reference 49DEAdea.govVisit source
- Reference 50UNODCunodc.orgVisit source
- Reference 51OREGONoregon.govVisit source
- Reference 52CATOcato.orgVisit source
- Reference 53FDAfda.govVisit source
- Reference 54LEGISLATIONlegislation.gov.ukVisit source
- Reference 55TGAtga.gov.auVisit source
- Reference 56LEGISLATIONlegislation.govt.nzVisit source
- Reference 57GESETZE-IM-INTERNETgesetze-im-internet.deVisit source
- Reference 58DROGY-INFOdrogy-info.czVisit source